{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:26Z","timestamp":1786982126421,"version":"build-2736575974"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11899-017-0387-9","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T01:54:31Z","timestamp":1495590871000},"page":"234-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multidisciplinary Management of Mycosis Fungoides\/S\u00e9zary Syndrome"],"prefix":"10.1007","volume":"12","author":[{"given":"Sara","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Villasenor-Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,24]]},"reference":[{"issue":"4","key":"387_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1172\/JCI24826","volume":"115","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798\u2013812. doi: 10.1172\/JCI24826 .","journal-title":"J Clin Invest"},{"issue":"10","key":"387_CR2","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385. doi: 10.1182\/blood-2004-09-3502 .","journal-title":"Blood"},{"issue":"3","key":"387_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40257-016-0177-5","volume":"17","author":"S Devata","year":"2016","unstructured":"Devata S, Wilcox RA. Cutaneous T-cell lymphoma: a review with a focus on targeted agents. Am J Clin Dermatol. 2016;17(3):225\u201337. doi: 10.1007\/s40257-016-0177-5 .","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"387_CR4","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/bjd.12909","volume":"170","author":"JJ Scarisbrick","year":"2014","unstructured":"Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now? Br J Dermatol. 2014;170(6):1226\u201336. doi: 10.1111\/bjd.12909 .","journal-title":"Br J Dermatol"},{"issue":"2","key":"387_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","volume":"64","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, et al. S\u00e9zary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011;64(2):352\u2013404. doi: 10.1016\/j.jaad.2010.08.037 .","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"387_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713\u201322. doi: 10.1182\/blood-2007-03-055749 .","journal-title":"Blood"},{"key":"387_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0351-0","author":"R Kohnken","year":"2016","unstructured":"\u2022 Kohnken R, Fabbro S, Hastings J, Porcu P, Mishra A. S\u00e9zary syndrome: clinical and biological aspects. Curr Hematol Malig Rep. 2016; doi: 10.1007\/s11899-016-0351-0 . This paper demonstrates the improved sensitivity of HTS over TCR PCR in diagnosis of MF as well as for detecting recurrences.","journal-title":"Curr Hematol Malig Rep"},{"key":"387_CR8","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kirsch IR, Watanabe R, O\u2019Malley JT, Williamson DW, Scott L-L, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308). doi: 10.1126\/scitranslmed.aa9122 . High throughout T cell receptor sequencing is shown to have benefits over existing modalities in the understanding, diagnosis and management of CTCL.","DOI":"10.1126\/scitranslmed.aa9122"},{"key":"387_CR9","doi-asserted-by":"publisher","unstructured":"\u2022 Weng W-K, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med. 2013;5(214). doi: 10.1126\/scitranslmed.3007420 . The authors demonstrate the high sensitivity and specificity of high throughput T cell receptor sequencing in detecting minimal residual disease in MF\/SS patients post allogeneic hematopoietic stem cell transplant.","DOI":"10.1126\/scitranslmed.3007420"},{"issue":"3","key":"387_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2133.2005.06649.x","volume":"153","author":"R Ponti","year":"2005","unstructured":"Ponti R, Quaglino P, Novelli M, Fierro MT, Comessatti A, Peroni A, et al. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction\/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides\/S\u00e9zary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings. Br J Dermatol. 2005;153(3):565\u201373. doi: 10.1111\/j.1365-2133.2005.06649.x .","journal-title":"Br J Dermatol"},{"issue":"3","key":"387_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2353\/jmoldx.2010.090123","volume":"12","author":"B Zhang","year":"2010","unstructured":"Zhang B, Beck AH, Taube JM, Kohler S, Seo K, Zwerner J, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn JMD. 2010;12(3):320\u20137. doi: 10.2353\/jmoldx.2010.090123 .","journal-title":"J Mol Diagn JMD"},{"issue":"2","key":"387_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2015.04.030","volume":"73","author":"KE Sufficool","year":"2015","unstructured":"\u2022 Sufficool KE, Lockwood CM, Abel HJ, Hagemann IS, Schumacher JA, Kelley TW, et al. T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. J Am Acad Dermatol. 2015;73(2):228\u2013236.e2. doi: 10.1016\/j.jaad.2015.04.030 . This paper demonstrates the improved sensitivity of HTS over TCR PCR in the diagnosis of MF as well as for detecting recurrences.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"387_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/CCO.0000000000000311","volume":"28","author":"JJ Scarisbrick","year":"2016","unstructured":"\u2022 Scarisbrick JJ. New drugs in cutaneous T-cell lymphomas. Curr Opin Oncol. 2016;28(5):384\u20139. doi: 10.1097\/CCO.0000000000000311 . This paper provides an excellent overview of both the current management of CTCL as well as new therapeutic modalities that are in various stages of investigation.","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"387_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archderm.139.7.857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857\u201366. doi: 10.1001\/archderm.139.7.857 .","journal-title":"Arch Dermatol"},{"issue":"1","key":"387_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdermsci.2009.10.010","volume":"57","author":"S Suzuki","year":"2010","unstructured":"Suzuki S, Ito K, Ito M, Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and S\u00e9zary syndrome. J Dermatol Sci. 2010;57(1):37\u201343. doi: 10.1016\/j.jdermsci.2009.10.010 .","journal-title":"J Dermatol Sci"},{"issue":"31","key":"387_CR16","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730\u20139. doi: 10.1200\/JCO.2009.27.7665 .","journal-title":"J Clin Oncol"},{"issue":"18","key":"387_CR17","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","volume":"18","author":"R Talpur","year":"2012","unstructured":"Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051\u201360. doi: 10.1158\/1078-0432.CCR-12-0604 .","journal-title":"Clin Cancer Res"},{"issue":"6","key":"387_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","volume":"40","author":"E Diamandidou","year":"1999","unstructured":"Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides\/S\u00e9zary syndrome. J Am Acad Dermatol. 1999;40(6):914\u201324. doi: 10.1016\/S0190-9622(99)70079-4 .","journal-title":"J Am Acad Dermatol"},{"issue":"32","key":"387_CR19","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"\u2022\u2022 Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766\u201373. doi: 10.1200\/JCO.2015.61.7142 . The results from a large, international collaboration that identified several independent prognostic markers that can be used to stratify advanced stage patients are presented in this paper.","journal-title":"J Clin Oncol"},{"key":"387_CR20","doi-asserted-by":"publisher","unstructured":"Tancr\u00e8de-Bohin E, Ionescu MA, de La Salmoni\u00e8re P, Dupuy A, Rivet J, Rybojad M, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol. 2004;140(9). doi: 10.1001\/archderm.140.9.1057 .","DOI":"10.1001\/archderm.140.9.1057"},{"issue":"9093","key":"387_CR21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/S0140-6736(05)63605-7","volume":"350","author":"E Dippel","year":"1997","unstructured":"Dippel E, Goerdt S, Assaf C, Stein H, Orfanos CE. Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet. 1997;350(9093):1776\u20137. doi: 10.1016\/S0140-6736(05)63605-7 .","journal-title":"Lancet"},{"issue":"9070","key":"387_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0140-6736(05)66242-3","volume":"350","author":"E Dippel","year":"1997","unstructured":"Dippel E, Schrag H, Goerdt S, Orfanos CE. Extracorporeal photopheresis and interferon-\u03b1 in advanced cutaneous T-cell lymphoma. Lancet. 1997;350(9070):32\u20133. doi: 10.1016\/S0140-6736(05)66242-3 .","journal-title":"Lancet"},{"issue":"4","key":"387_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jaad.2009.01.044","volume":"64","author":"KG Evans","year":"2011","unstructured":"Evans KG, Troxel AB, DeNardo BJ, Introcaso CE, Rook AH, Kim EJ. Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides\/S\u00e9zary syndrome. J Am Acad Dermatol. 2011;64(4):682\u20139. doi: 10.1016\/j.jaad.2009.01.044 .","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"387_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2133.2005.06676.x","volume":"153","author":"C-D Klemke","year":"2005","unstructured":"Klemke C-D, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol. 2005;153(1):118\u201324. doi: 10.1111\/j.1365-2133.2005.06676.x .","journal-title":"Br J Dermatol"},{"key":"387_CR25","doi-asserted-by":"publisher","unstructured":"Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 49(13):2859\u201368. doi: 10.1016\/j.ejca.2013.04.018 .","DOI":"10.1016\/j.ejca.2013.04.018"},{"issue":"9","key":"387_CR26","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","volume":"152","author":"S Santen van","year":"2016","unstructured":"\u2022\u2022 van Santen S, Roach REJ, van Doorn R, Horv\u00e1th B, Bruijn MS, Sanders CJG, et al. Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol. 2016;152(9):992\u20131000. doi: 10.1001\/jamadermatol.2016.1597 . This is a prospective study of 203 FMF patients that identifies criteria that can be used to distinguish between indolent versus aggressive subtypes thus arguing that not all FMF patients have a worse prognosis.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"387_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/archderm.138.2.191","volume":"138","author":"R Doorn van","year":"2002","unstructured":"van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138(2):191\u20138. doi: 10.1001\/archderm.138.2.191 .","journal-title":"Arch Dermatol"},{"issue":"6","key":"387_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/archderm.144.6.738","volume":"144","author":"P Gerami","year":"2008","unstructured":"Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144(6):738\u201346. doi: 10.1001\/archderm.144.6.738 .","journal-title":"Arch Dermatol"},{"issue":"6","key":"387_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/archdermatol.2010.101","volume":"146","author":"JS Lehman","year":"2010","unstructured":"Lehman JS, Cook-Norris RH, Weed BR, Weenig RH, Gibson LE, Weaver AL, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010;146(6):607\u201313. doi: 10.1001\/archdermatol.2010.101 .","journal-title":"Arch Dermatol"},{"issue":"3","key":"387_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2009.03.014","volume":"62","author":"C Muniesa","year":"2010","unstructured":"Muniesa C, Estrach T, Pujol RM, Gallardo F, Garcia-Muret P, Climent J, et al. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol. 2010;62(3):418\u201326. doi: 10.1016\/j.jaad.2009.03.014 .","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"387_CR31","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","volume":"119","author":"MF Benner","year":"2012","unstructured":"Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643\u20139. doi: 10.1182\/blood-2011-08-376319 .","journal-title":"Blood"},{"issue":"2","key":"387_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jaad.2016.03.009","volume":"75","author":"E Hodak","year":"2016","unstructured":"\u2022\u2022 Hodak E, Amitay-Laish I, Atzmony L, Prag-Naveh H, Yanichkin N, Barzilai A, et al. New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol. 2016;75(2):347\u201355. doi: 10.1016\/j.jaad.2016.03.009 . This is a retrospective review of 49 patients with follicultropic MF that defined two subtypes of FMF patients based on clinicopathologic features and found that prognosis differed between the groups.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"387_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2340\/00015555-1476","volume":"93","author":"P Mantaka","year":"2013","unstructured":"Mantaka P, Helsing P, Gjersvik P, Bassarova A, Clausen O, Delabie J. Clinical and histopathological features of folliculotropic mycosis fungoides: a Norwegian patient series. Acta Derm Venereol. 2013;93(3):325\u20139. doi: 10.2340\/00015555-1476 .","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"387_CR34","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1097\/PAS.0b013e3180439bdc","volume":"31","author":"P Gerami","year":"2007","unstructured":"Gerami P, Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31(9):1430\u20138. doi: 10.1097\/PAS.0b013e3180439bdc .","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"387_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cup.12423","volume":"42","author":"C Demirkesen","year":"2015","unstructured":"Demirkesen C, Esirgen G, Engin B, Songur A, O\u011fuz O. The clinical features and histopathologic patterns of folliculotropic mycosis fungoides in a series of 38 cases: clinical features of FMF. J Cutan Pathol. 2015;42(1):22\u201331. doi: 10.1111\/cup.12423 .","journal-title":"J Cutan Pathol"},{"issue":"6","key":"387_CR36","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1001\/archdermatol.2010.93","volume":"146","author":"L Cerroni","year":"2010","unstructured":"Cerroni L. Pilotropic mycosis fungoides: a clinicopathologic variant of mycosis fungoides yet to be completely understood. Arch Dermatol. 2010;146(6):662\u20134. doi: 10.1001\/archdermatol.2010.93 .","journal-title":"Arch Dermatol"},{"issue":"3","key":"387_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/cup.12399","volume":"42","author":"C Tomasini","year":"2015","unstructured":"Tomasini C, Kempf W, Novelli M, Fava P, Annessi G, Rongioletti F, et al. Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases: spiky follicular mycosis fungoides. J Cutan Pathol. 2015;42(3):164\u201372. doi: 10.1111\/cup.12399 .","journal-title":"J Cutan Pathol"},{"issue":"9","key":"387_CR38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"\u2022 Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011\u20139. doi: 10.1038\/ng.3356 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Nat Genet"},{"key":"387_CR39","doi-asserted-by":"publisher","unstructured":"\u2022 Kiel MJ, Sahasrabuddhe AA, Rolland DCM, Velusamy T, Chung F, Schaller M, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK\u2013STAT pathway in S\u00e9zary syndrome. Nat Commun. 2015 ;6. doi: 10.1038\/ncomms9470 . One of several recent papers demonstrating mutational changes in CTCL.","DOI":"10.1038\/ncomms9470"},{"issue":"12","key":"387_CR40","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ng.3444","volume":"47","author":"L Wang","year":"2015","unstructured":"\u2022 Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, et al. Genomic profiling of S\u00e9zary syndrome identifies alterations of key T-cell signaling and differentiation genes. Nat Genet. 2015;47(12):1426\u201334. doi: 10.1038\/ng.3444 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Nat Genet"},{"issue":"12","key":"387_CR41","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","volume":"47","author":"AC Silva Almeida da","year":"2015","unstructured":"\u2022 da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, et al. The mutational landscape of cutaneous T-cell lymphoma and S\u00e9zary syndrome. Nat Genet. 2015;47(12):1465\u201370. doi: 10.1038\/ng.3442 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Nat Genet"},{"issue":"4","key":"387_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2015.07.009","volume":"162","author":"G Teng","year":"2015","unstructured":"\u2022 Teng G, Maman Y, Resch W, Kim M, Yamane A, Qian J, et al. RAG represents a widespread threat to the lymphocyte genome. Cell. 2015;162(4):751\u201365. doi: 10.1016\/j.cell.2015.07.009 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Cell"},{"issue":"1","key":"387_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27\u201340. doi: 10.1016\/j.cell.2010.11.055 .","journal-title":"Cell"},{"issue":"9","key":"387_CR44","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/ng.3370","volume":"47","author":"A Ungewickell","year":"2015","unstructured":"\u2022 Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, et al. Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47(9):1056\u201360. doi: 10.1038\/ng.3370 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Nat Genet"},{"issue":"4","key":"387_CR45","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","volume":"126","author":"LY McGirt","year":"2015","unstructured":"\u2022 McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood. 2015;126(4):508\u201319. doi: 10.1182\/blood-2014-11-611194 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Blood"},{"key":"387_CR46","doi-asserted-by":"publisher","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5). doi: 10.1016\/j.immuni.2016.04.020 .","DOI":"10.1016\/j.immuni.2016.04.020"},{"issue":"13","key":"387_CR47","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","volume":"123","author":"JP Vaqu\u00e9","year":"2014","unstructured":"\u2022 Vaqu\u00e9 JP, G\u00f3mez-L\u00f3pez G, Mons\u00e1lvez V, Varela I, Mart\u00ednez N, P\u00e9rez C, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123(13):2034\u201343. doi: 10.1182\/blood-2013-05-504308 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"Blood"},{"issue":"6","key":"387_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","volume":"25","author":"G Bonizzi","year":"2004","unstructured":"Bonizzi G, Karin M. The two NF-\u03baB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280\u20138. doi: 10.1016\/j.it.2004.03.008 .","journal-title":"Trends Immunol"},{"issue":"6","key":"387_CR49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.immuni.2005.09.014","volume":"23","author":"K Sommer","year":"2005","unstructured":"Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno-Garc\u00eda ME, Ovechkina YL, et al. Phosphorylation of the CARMA1 linker controls NF-\u03baB activation. Immunity. 2005;23(6):561\u201374. doi: 10.1016\/j.immuni.2005.09.014 .","journal-title":"Immunity"},{"issue":"5870","key":"387_CR50","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676\u20139. doi: 10.1126\/science.1153629 .","journal-title":"Science"},{"issue":"13","key":"387_CR51","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1084\/jem.20140987","volume":"211","author":"M Nakagawa","year":"2014","unstructured":"\u2022 Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, et al. Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma. J Exp Med. 2014;211(13):2497\u2013505. doi: 10.1084\/jem.20140987 . One of several recent papers demonstrating mutational changes in CTCL.","journal-title":"J Exp Med"},{"issue":"4","key":"387_CR52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000080852","volume":"209","author":"JC Hassel","year":"2004","unstructured":"Hassel JC, Meier R, Joller-Jemelka H, Burg G, Dummer R. Serological Immunomarkers in cutaneous T cell lymphoma. Dermatology. 2004;209(4):296\u2013300. doi: 10.1159\/000080852 .","journal-title":"Dermatology"},{"issue":"8","key":"387_CR53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/exd.12455","volume":"23","author":"LJ Geskin","year":"2014","unstructured":"Geskin LJ, Akilov OE, Lin Y, Lokshin AE. Distinct age-matched serum biomarkers profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol. 2014;23(8):598\u2013600. doi: 10.1111\/exd.12455 .","journal-title":"Exp Dermatol"},{"issue":"1","key":"387_CR54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/JID.2015.360","volume":"136","author":"C Hurabielle","year":"2016","unstructured":"\u2022 Hurabielle C, Michel L, Ram-Wolff C, Battistella M, Jean-Louis F, Beylot-Barry M, et al. Expression of S\u00e9zary biomarkers in the blood of patients with erythrodermic mycosis fungoides. J Invest Dermatol. 2016;136(1):317\u201320. doi: 10.1038\/JID.2015.360 . One of several recent papers regarding potential novel biomarkers in CTCL.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"387_CR55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00403-014-1501-7","volume":"306","author":"S Morimura","year":"2014","unstructured":"\u2022 Morimura S, Sugaya M, Suga H, Miyagaki T, Ohmatsu H, Fujita H, et al. TOX expression in different subtypes of cutaneous lymphoma. Arch Dermatol Res. 2014;306(9):843\u20139. doi: 10.1007\/s00403-014-1501-7 . One of several recent papers regarding potential novel biomarkers in CTCL.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"387_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjd.14508","volume":"175","author":"AMR Schrader","year":"2016","unstructured":"\u2022 Schrader AMR, Jansen PM, Willemze R. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4+ CD8\u2212 phenotype. Br J Dermatol. 2016;175(2):382\u20136. doi: 10.1111\/bjd.14508 . One of several recent papers regarding potential novel biomarkers in CTCL.","journal-title":"Br J Dermatol"},{"issue":"8","key":"387_CR57","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","volume":"42","author":"F Trautinger","year":"2006","unstructured":"Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome. Eur J Cancer Oxf Engl 1990. 2006;42(8):1014\u201330. doi: 10.1016\/j.ejca.2006.01.025 .","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"Suppl 6","key":"387_CR58","doi-asserted-by":"publisher","first-page":"vi149","DOI":"10.1093\/annonc\/mdt242","volume":"24","author":"R Willemze","year":"2013","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(Suppl 6):vi149\u201354. doi: 10.1093\/annonc\/mdt242 .","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9","key":"387_CR59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","volume":"14","author":"SM Horwitz","year":"2016","unstructured":"Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN guidelines insights: non-Hodgkin\u2019s lymphomas, version 3.2016. J Natl Compr Cancer Netw JNCCN. 2016;14(9):1067\u201379.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"4","key":"387_CR60","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11899-015-0293-y","volume":"10","author":"CG Chung","year":"2015","unstructured":"Chung CG, Poligone B. Cutaneous T cell lymphoma: an update on pathogenesis and systemic therapy. Curr Hematol Malig Rep. 2015;10(4):468\u201376. doi: 10.1007\/s11899-015-0293-y .","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"387_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CFM Hughes","year":"2015","unstructured":"Hughes CFM, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71\u201381. doi: 10.1182\/blood-2014-07-588236 .","journal-title":"Blood"},{"issue":"12","key":"387_CR62","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1002\/ajh.24564","volume":"91","author":"W Hanel","year":"2016","unstructured":"Hanel W, Briski R, Ross CW, Anderson TF, Kaminski MS, Hristov AC, et al. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and Sezary syndrome. Am J Hematol. 2016;91(12):E491\u20135. doi: 10.1002\/ajh.24564 .","journal-title":"Am J Hematol"},{"issue":"2","key":"387_CR63","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/1097-0142(197608)38:2<683::AID-CNCR2820380210>3.0.CO;2-V","volume":"38","author":"BA Gilchrest","year":"1976","unstructured":"Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer. 1976;38(2):683\u20139. doi: 10.1002\/1097-0142(197608)38:2<683::AID-CNCR2820380210>3.0.CO;2-V .","journal-title":"Cancer"},{"issue":"1","key":"387_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","volume":"74","author":"EA Olsen","year":"2016","unstructured":"\u2022\u2022 Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27\u201358. doi: 10.1016\/j.jaad.2015.09.033 . This is the consensus statement released by the USCLC detailing guidelines for the use of phototherapy in CTCL.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"387_CR65","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1985::AID-CNCR16>3.0.CO;2-O","volume":"85","author":"GW Jones","year":"1999","unstructured":"Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the S\u00e9zary syndrome). Cancer. 1999;85(9):1985\u201395. doi: 10.1002\/(SICI)1097-0142(19990501)85:9<1985::AID-CNCR16>3.0.CO;2-O .","journal-title":"Cancer"},{"issue":"2","key":"387_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejmp.2010.09.001","volume":"27","author":"S Diamantopoulos","year":"2011","unstructured":"Diamantopoulos S, Platoni K, Dilvoi M, Nazos I, Geropantas K, Maravelis G, et al. Clinical implementation of total skin electron beam (TSEB) therapy: a review of the relevant literature. Phys Med. 2011;27(2):62\u20138. doi: 10.1016\/j.ejmp.2010.09.001 .","journal-title":"Phys Med"},{"issue":"4","key":"387_CR67","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaad.2007.12.016","volume":"58","author":"CE Introcaso","year":"2008","unstructured":"Introcaso CE, Micaily B, Richardson SK, Junkins-Hopkins JM, Yoon JS, Kim EJ, et al. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in S\u00e9zary syndrome. J Am Acad Dermatol. 2008;58(4):592\u20135. doi: 10.1016\/j.jaad.2007.12.016 .","journal-title":"J Am Acad Dermatol"},{"key":"387_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.08.019","author":"M Chowdhary","year":"2016","unstructured":"Chowdhary M, Chhabra AM, Kharod S, Marwaha G. Total skin electron beam therapy in the treatment of mycosis fungoides: a review of conventional and low-dose regimens. Clin Lymphoma Myeloma Leuk. 2016; doi: 10.1016\/j.clml.2016.08.019 .","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"387_CR69","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaad.2012.09.056","volume":"68","author":"RS Klein","year":"2013","unstructured":"Klein RS, Dunlop JD, Samimi SS, Morrissey KA, Evans KG, Gardner JM, et al. Improvement in peripheral blood disease burden in patients with S\u00e9zary syndrome and leukemic mycosis fungoides after total skin electron beam therapy. J Am Acad Dermatol. 2013;68(6):972\u20137. doi: 10.1016\/j.jaad.2012.09.056 .","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"387_CR70","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","volume":"16","author":"RT Hoppe","year":"2003","unstructured":"Hoppe RT. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003;16(4):347\u201354. doi: 10.1111\/j.1396-0296.2003.01647.x .","journal-title":"Dermatol Ther"},{"issue":"5","key":"387_CR71","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/0360-3016(94)00590-H","volume":"32","author":"M Becker","year":"1995","unstructured":"Becker M, Hoppe RT, Knox SJ. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol. 1995;32(5):1445\u20139. doi: 10.1016\/0360-3016(94)00590-H .","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"387_CR72","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","volume":"72","author":"RT Hoppe","year":"2015","unstructured":"\u2022\u2022 Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286\u201392. doi: 10.1016\/j.jaad.2014.10.014 . The authors pool data from three clinical trials investigating the use of low dose TSEBT to demonstrate the utility of this approach in select MF patients given its efficacy, limited toxicities and ability to be used recurrently.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"387_CR73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijrobp.2015.01.047","volume":"92","author":"MR Kamstrup","year":"2015","unstructured":"Kamstrup MR, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, et al. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol. 2015;92(1):138\u201343. doi: 10.1016\/j.ijrobp.2015.01.047 .","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"387_CR74","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.08.041","volume":"93","author":"K Elsayad","year":"2015","unstructured":"\u2022\u2022 Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, et al. Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol. 2015;93(5):1077\u201386. doi: 10.1016\/j.ijrobp.2015.08.041 . This is a retrospective review of 45 patients that compared conventional to low dose TSEBT and a found a non-significant trend in conventional dose towards a more sustained clinical benefit.","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"387_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/CCO.0000000000000048","volume":"26","author":"AO Huen","year":"2014","unstructured":"\u2022 Huen AO, Rook AH. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol. 2014;26(2):237\u201344. doi: 10.1097\/CCO.0000000000000048 . This is an excellent review of the use of toll receptor agonists for the treatment of cutaneous malignancies.","journal-title":"Curr Opin Oncol"},{"issue":"Suppl 66","key":"387_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.0366-077X.2003.05630.x","volume":"149","author":"R Dummer","year":"2003","unstructured":"Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003;149(Suppl 66):57\u20138. doi: 10.1046\/j.0366-077X.2003.05630.x .","journal-title":"Br J Dermatol"},{"issue":"12","key":"387_CR77","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","volume":"126","author":"AH Rook","year":"2015","unstructured":"\u2022\u2022 Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452\u201361. doi: 10.1182\/blood-2015-02-630335 . This is a phase I trial that demonstrates the safety and outstanding efficacy of topical resiquimod, a TLR 7 and 8 agonist, in refractory early stage MF and provides evidence of this topical therapy stimulating a systemic immune response.","journal-title":"Blood"},{"issue":"6","key":"387_CR78","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2230.2006.02208.x","volume":"31","author":"N Ariffin","year":"2006","unstructured":"Ariffin N, Khorshid M. Treatment of mycosis fungoides with imiquimod 5% cream. Clin Exp Dermatol. 2006;31(6):822\u20133. doi: 10.1111\/j.1365-2230.2006.02208.x .","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"387_CR79","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","volume":"52","author":"MJ Deeths","year":"2005","unstructured":"Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275\u201380. doi: 10.1016\/j.jaad.2004.04.049 .","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"387_CR80","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","volume":"138","author":"KR Suchin","year":"2002","unstructured":"Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol. 2002;138(9):1137\u20139. doi: 10.1001\/archderm.138.9.1137 .","journal-title":"Arch Dermatol"},{"issue":"3","key":"387_CR81","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","volume":"174","author":"KB Gorden","year":"2005","unstructured":"Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174(3):1259\u201368. doi: 10.4049\/jimmunol.174.3.1259 .","journal-title":"J Immunol"},{"issue":"4","key":"387_CR82","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365. doi: 10.1182\/blood-2003-01-0039 .","journal-title":"Blood"},{"issue":"1","key":"387_CR83","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","volume":"19","author":"C Deng","year":"2013","unstructured":"Deng C, Pan B, O\u2019Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22\u20137. doi: 10.1158\/1078-0432.CCR-12-0290 .","journal-title":"Clin Cancer Res"},{"issue":"7","key":"387_CR84","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2146\/ajhp110608","volume":"70","author":"AM Bradley","year":"2013","unstructured":"Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm. 2013;70(7):589\u201397. doi: 10.2146\/ajhp110608 .","journal-title":"Am J Health Syst Pharm"},{"issue":"32","key":"387_CR85","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1200\/JCO.2015.61.9486","volume":"33","author":"HM Prince","year":"2015","unstructured":"Prince HM. CD30 as a target for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2015;33(32):3691\u20136. doi: 10.1200\/JCO.2015.61.9486 .","journal-title":"J Clin Oncol"},{"issue":"4","key":"387_CR86","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","volume":"92","author":"E Diamandidou","year":"1998","unstructured":"Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92(4):1150\u20139.","journal-title":"Blood"},{"issue":"1","key":"387_CR87","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jamadermatol.2014.1629","volume":"151","author":"T Mehra","year":"2015","unstructured":"Mehra T, Ikenberg K, Moos RM, Benz R, Nair G, Schanz U, et al. Brentuximab as a treatment for CD30+ mycosis fungoides and S\u00e9zary syndrome. JAMA Dermatol. 2015;151(1):73\u20137. doi: 10.1001\/jamadermatol.2014.1629 .","journal-title":"JAMA Dermatol"},{"issue":"5","key":"387_CR88","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/bjh.13220","volume":"168","author":"M Criscuolo","year":"2015","unstructured":"Criscuolo M, Fianchi L, Voso MT, Pagano L. Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin. Br J Haematol. 2015;168(5):617. doi: 10.1111\/bjh.13220 .","journal-title":"Br J Haematol"},{"issue":"32","key":"387_CR89","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"\u2022\u2022 Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759\u201365. doi: 10.1200\/JCO.2014.60.3787 . This is a phase II trial that demonstrates the safety and efficacy of brentuximab in CD30+ MF\/SS and found a similar overall response rate regardless of degree of CD30 positivity.","journal-title":"J Clin Oncol"},{"issue":"32","key":"387_CR90","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"\u2022\u2022 Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750\u20138. doi: 10.1200\/JCO.2014.60.3969 . This is another phase II study that demonstrates clinical benefit of brentuximab in patients with refractory or advanced MF\/SS in patients with a range of CD30 expression.","journal-title":"J Clin Oncol"},{"key":"387_CR91","doi-asserted-by":"crossref","unstructured":"Kim YH, Sean W, Horwitz SM, Duvic M, Dummer R, Scarisbrick JJ, et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician\u2019s choice (methotrexate or bexarotene): the phase 3 Alcanza study [abstract]. In: American Society of Hematology 58th Annual Meeting and Exposition. 2016; San Diego.","DOI":"10.1182\/blood.V128.22.182.182"},{"issue":"23","key":"387_CR92","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(23):2698\u2013704. doi: 10.1200\/JCO.2015.65.9789 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"387_CR93","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","volume":"128","author":"M Khodadoust","year":"2016","unstructured":"Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, et al. Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and Sezary syndrome: clinical efficacy in a CITN multicenter phase 2 study. Blood. 2016;128(22):181.","journal-title":"Blood"},{"issue":"29","key":"387_CR94","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492\u20139. doi: 10.1200\/JCO.2010.29.3241 .","journal-title":"J Clin Oncol"},{"issue":"29","key":"387_CR95","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","volume":"32","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347\u20138.","journal-title":"J Clin Oncol"},{"issue":"25","key":"387_CR96","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","volume":"23","author":"A Molina","year":"2005","unstructured":"Molina A. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005;23(25):6163\u201371. doi: 10.1200\/JCO.2005.02.774 .","journal-title":"J Clin Oncol"},{"issue":"14","key":"387_CR97","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","volume":"28","author":"M Duvic","year":"2010","unstructured":"Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28(14):2365\u201372. doi: 10.1200\/JCO.2009.25.8301 .","journal-title":"J Clin Oncol"},{"issue":"3","key":"387_CR98","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3324\/haematol.2013.098145","volume":"99","author":"A Masson de","year":"2014","unstructured":"de Masson A, Beylot-Barry M, Bouaziz J-D, Peffault de Latour R, Aubin F, Garciaz S, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99(3):527\u201334. doi: 10.3324\/haematol.2013.098145 .","journal-title":"Haematologica"},{"issue":"7","key":"387_CR99","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/bmt.2011.201","volume":"47","author":"VR Paralkar","year":"2012","unstructured":"Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant. 2012;47(7):940\u20135. doi: 10.1038\/bmt.2011.201 .","journal-title":"Bone Marrow Transplant"},{"key":"387_CR100","doi-asserted-by":"publisher","unstructured":"Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews. Chichester: Wiley; 2013. doi: 10.1002\/14651858.CD008908.pub3 .","DOI":"10.1002\/14651858.CD008908.pub3"},{"key":"387_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv473","author":"C Hosing","year":"2015","unstructured":"\u2022\u2022 Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015; doi: 10.1093\/annonc\/mdv473 . This paper provides data from a prospective case series of 47 patients who underwent HSCT for advanced MF\/SS at a single institution.","journal-title":"Ann Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0387-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T06:18:54Z","timestamp":1602137934000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0387-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,24]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0387-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,24]]}}}